Patients Access solutions: the missing link that prevents biopharma i... We live in unprecedented times, where innovation in biosciences continues to accelerate.
Pharma Market Access Access solutions: the missing link that prevents biopharma i... We live in unprecedented times, where innovation in biosciences continues to accelerate.
News Amgen agrees $26bn for Horizon following Sanofi withdrawal In a fresh update, Bloomberg has reported that US biotech Amg
Views & Analysis Results gap between digital leaders and laggards Karl Goossens, director of commercial analytics at Veeva Systems Europe, recently spoke with pharmaphorum, discussing how effective omnichannel execution drives revenue and productivity.
Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
News Phesi launches AI-driven trial accelerator, saving $7m per t... Yesterday, global provider of patient-centric data analytics, Phesi launched its AI-driven Trial Accelerator Platform, an
News Amgen's big reveal of obesity data falls a little flat Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
